Louisiana State Employees Retirement System Buys 1,600 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Louisiana State Employees Retirement System raised its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 114,300 shares of the biotechnology company’s stock after acquiring an additional 1,600 shares during the period. Louisiana State Employees Retirement System’s holdings in ADMA Biologics were worth $1,960,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. State Street Corp increased its holdings in shares of ADMA Biologics by 61.4% in the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after purchasing an additional 4,945,063 shares during the last quarter. Perpetual Ltd purchased a new position in ADMA Biologics during the 4th quarter valued at approximately $62,300,000. Lord Abbett & CO. LLC bought a new stake in ADMA Biologics in the 3rd quarter worth approximately $61,858,000. Principal Financial Group Inc. raised its holdings in shares of ADMA Biologics by 785.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock worth $23,872,000 after acquiring an additional 1,059,394 shares in the last quarter. Finally, First Turn Management LLC bought a new position in shares of ADMA Biologics during the 3rd quarter valued at approximately $13,293,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $15.90 on Friday. The business’s 50 day moving average price is $17.35 and its 200-day moving average price is $17.74. ADMA Biologics, Inc. has a fifty-two week low of $5.02 and a fifty-two week high of $23.64. The company has a market cap of $3.76 billion, a P/E ratio of 56.79 and a beta of 0.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

Insiders Place Their Bets

In other news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the sale, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.70% of the stock is owned by insiders.

Analyst Ratings Changes

ADMA has been the topic of several research reports. HC Wainwright boosted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Raymond James boosted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.